|
Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo). |
|
|
Research Funding - Amgen (Inst) |
Travel, Accommodations, Expenses - Daiichi Sankyo (I) |
|
|
Employment - Analytica Laser; Evidera |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merrimack; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merrimack; novartis |
Speakers' Bureau - amgen; Bayer; Celgene; roche; sanofi |
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst) |
Other Relationship - Celgene; emd serono; Halozyme; Roche; sanofi |
|
|
Research Funding - Employed by Evidera which received funding through Halozyme |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Halozyme |
Research Funding - Halozyme |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Genentech; Halozyme; Janssen; LEO Pharma; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Genentech; Halozyme; Janssen; LEO Pharma; Pfizer; Sanofi |
Research Funding - Amgen (Inst) |
Travel, Accommodations, Expenses - Halozyme; Janssen; Pfizer |